ESR1 PvuII polymorphism: from risk factor to prognostic and predictive factor of the success of primary systemic therapy in advanced breast cancer.

doi:10.1186/s12885-021-09083-x

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

ESR1 PvuII polymorphism: from risk factor to prognostic and predictive factor of the success of primary systemic therapy in advanced breast cancer.

BMC cancer - 20 Dec 2021

Karsono Ramadhan, Haryono Samuel J, Karsono Bambang, Harahap Wirsma Arif, Pratiwi Yulia, Aryandono Teguh

Abstract excerpt

BACKGROUND: The ESR1 gene encodes Estrogen Receptor alpha (ERα), which plays a role in the tumourigenesis of breast cancer. A single nucleotide polymorphism (SNP) in intron 1 of this gene called ESR1 PvuII (rs2234693) has been reported to increase the risk of breast cancer. This study aimed to investigate the ESR1 PvuII polymorphism as a prognostic and predictive factor guiding the choice of therapy for advanced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biopsy

Share to Breast

Share to Drug Resistance, Neoplasm

Share to Estrogen Receptor alpha

Share to Kaplan-Meier Estimate

Share to Polymorphism, Restriction Fragment Length

Share to Risk Assessment

Source

Open in PubMed Open full text

Identifiers

PMID: 34930150
DOI: 10.1186/s12885-021-09083-x
PMCID: PMC8686387

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ESR1 PvuII polymorphism: from risk factor to prognostic and predictive factor of the success of primary systemic therapy in advanced breast cancer.PMID 34930150Read ↗

The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival.Semantic proximity Read ↗

Association of ESRα-Pvull and ESRα-Xbal Polymorphisms with Breast Cancer Susceptibility in an Iranian Population: A Hospital-Based Case-Control Study.Semantic proximity Read ↗

Association Between ESR1 PvuII, XbaI, and P325P Polymorphisms and Breast Cancer Susceptibility: A Meta-Analysis.Semantic proximity Read ↗

Menopausal status modifies breast cancer risk associated with ESR1 PvuII and XbaI polymorphisms in Asian women: a HuGE review and meta-analysis.Semantic proximity Read ↗

Estrogen receptor alpha (ERS1) SNPs c454-397T>C (PvuII) and c454-351A>G (XbaI) are risk biomarkers for breast cancer development.Semantic proximity Read ↗

Impact of ESR1 Polymorphisms on Risk of Breast Cancer in the Chinese Han PopulationSemantic proximity Read ↗

Impact of ESR1 Polymorphisms on Risk of Breast Cancer in the Chinese Han Population.Semantic proximity Read ↗

Association between estrogen receptor 1 (ESR1) genetic variations and cancer risk: a meta-analysis.Semantic proximity Read ↗

Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer.Semantic proximity Read ↗

Association between ERα gene Pvu II polymorphism and breast cancer susceptibility: A meta-analysis.Semantic proximity Read ↗

Association of ESR1, HER1, and HER2 Polymorphisms with Breast Cancer Risk in the KP Population, A Case-Control Study.Semantic proximity Read ↗

The Role of ESR1 Gene Polymorphic Markers in the Development of Breast Cancer and Resistance to Tamoxifen Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.